CGEN (Compugen) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGEN Compugen Ltd CGEN
59 GF Score
Price $2.36
GF Value $5.19
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Compugen Net Loan?

Net Loan only applies to banks and insurance companies.

CGEN
59GF Score
Compugen Ltd CGEN
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Compugen (CGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Compugen stock appears to be undervalued. The current stock price of $2.36 is trading 54.6% below its estimated GF Value™ of $5.19. GuruFocus considers Compugen to be Possible Value Trap.

Key valuation signals for CGEN:

  • Net Loan:
  • GF Value™: $5.19 vs. price of $2.36 (54.6% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compugen Business Description

Other Exchanges CGEN:Israel
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
59GF Score

Get the complete analysis for CGEN

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price
$5.19
GF Value